What Myovant Sciences does

Myovant Sciences is a specialty biopharmaceutical company developing and commercializing novel small-molecule therapies built on the relugolix platform. Its two marketed products are ORGOVYX (relugolix), indicated for advanced prostate cancer treatment, and MYFEMBREE (relugolix, estradiol, and norethindrone acetate), positioned across women's health indications including endometriosis and uterine fibroids. The company serves defined patient populations — men with advanced or castration-sensitive prostate cancer and women with endometriosis/uterine fibroids — through an enterprise specialty-pharma field-sales motion targeting healthcare providers and payers in the United States (North America accounts for 44.17% regional share of the 2025 endometriosis treatment market where Myovant competes).

Revenue is generated through branded pharmaceutical product sales of ORGOVYX and MYFEMBREE, with pricing negotiated with payers rather than publicly disclosed. The go-to-market relies on traditional specialty-pharma distribution channels reaching physicians and patients. Myovant is actively expanding its endometriosis clinical pipeline to include non-hormonal targeted therapies and long-term disease-management solutions, addressing a market projected to grow from USD 2.01 billion (2025) to USD 5.73–5.74 billion by 2034 at ~12.35–12.37% CAGR. ORGOVYX competes in a castration-sensitive prostate cancer market sized at USD 4.3 billion (2024) with 13.2% CAGR through 2034.

In March 2023, Myovant was acquired by Sumitovant Biopharma Ltd. for $1.7 billion, taking the company private and folding it into the Sumitomo Pharma America corporate ecosystem. Founded in 2016, headquartered in Brisbane, California, and operating with 501–1,000 employees, Myovant raised approximately $540 million across multiple private rounds (2017–2020) prior to acquisition, with Dainippon Sumitomo Pharma, Novaquest Capital Management, and Hercules Capital among its backers. As a wholly owned subsidiary, Myovant now leverages its parent's capital, R&D infrastructure, and commercial reach to accelerate pipeline development and franchise expansion.

Name

Myovant Sciences

Legal name

Myovant Sciences Ltd.

Website

https://myovant.com

Company type

Private

Founded year

2016

Operating status

Acquired

Headcount range

501–1,000 employees

Short description

Myovant Sciences is a specialty biopharmaceutical company developing relugolix-based therapies — ORGOVYX for advanced prostate cancer and MYFEMBREE for women's health — serving prostate cancer patients and women with endometriosis and uterine fibroids as a Sumitovant Biopharma subsidiary.

Ownership category

akta.pro rank

Product category

Specialty Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industry

Urologic Oncology (HLAKAOAB)

Keywords

• Specialty biopharmaceuticals
• Prostate cancer therapy
• Women's health therapeutics
• Endometriosis treatment
• Novel drug development

Headquarters

HQ city

Brisbane

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Pharmaceutical product sales: Myovant Sciences generates revenue from commercialization of its proprietary drug products ORGOVYX and MYFEMBREE. As a specialty biopharmaceutical company operating within Sumitovant Biopharma since the March 2023 acquisition, the revenue mix is anchored in product sales of approved therapies, with potential future revenue from expanded indications and pipeline products.

Go-to-market motion1 record

Core offering

Myovant Sciences is a specialty biopharmaceutical company that develops and commercializes novel therapies for defined patient populations in prostate cancer and women's health. Its two lead products are ORGOVYX, an oral therapy for advanced prostate cancer, and MYFEMBREE, a therapy for women's health indications including endometriosis and uterine fibroids, supported by an actively expanding clinical pipeline for long-term endometriosis disease management.

Product overview

Myovant Sciences operates as a specialty biopharmaceutical company developing a focused portfolio of novel therapies rather than a platform-plus-modules software product. Its two named therapeutic products, ORGOVYX and MYFEMBREE, are the cornerstone offerings supported by an expanding clinical pipeline in women's health (endometriosis, uterine fibroids) and castration-sensitive prostate cancer. Following its March 2023 acquisition by Sumitovant Biopharma for $1.7 billion, Myovant's portfolio is positioned for accelerated development, and the company is cited as a key pharmaceutical player expanding clinical pipelines for long-term disease management in endometriosis and PCOS.

Differentiator

Problem solved

Functional benefit

Brands

• ORGOVYX: Novel therapy developed by Myovant Sciences, cited in connection with the Sumitovant acquisition.
• MYFEMBREE

Products and services

• ORGOVYX (relugolix)

Quantifiable outcome

• Acquired by Sumitovant Biopharma for $1.7 billion in March 2023, signaling valuation of Myovant's portfolio of novel therapies.
• +1 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• AbbVie: Global pharmaceutical leader with a major women's health franchise (including Orilissa/Oriahnn for endometriosis) and oncology portfolio. Directly comparable as a key competitor cited in the endometriosis market alongside Myovant.
• Bayer AG: Diversified life sciences company with a significant women's health and oncology portfolio (e.g., Visanne for endometriosis). Named alongside Myovant as a key endometriosis market player.
• Pfizer: Global pharmaceutical leader with established women's health and oncology franchises. Cited alongside Myovant as a key pharmaceutical company expanding endometriosis clinical pipelines.
• AstraZeneca: Global biopharmaceutical company with major oncology and women's health franchises. Comparable to Myovant as a broader incumbent with overlapping therapeutic areas.
• Eli Lilly: Diversified global pharmaceutical leader with significant oncology and women's health investments. Comparable broad-incumbent competitor operating in Myovant's therapeutic categories.

Direct peers

• Astellas Pharma: Specialty biopharmaceutical company with deep urology and prostate cancer franchise (Xtandi). Directly comparable to Myovant's ORGOVYX positioning in advanced prostate cancer.
• Organon & Co. Women's health-focused specialty biopharmaceutical company spun out from Merck. Directly comparable to Myovant's MYFEMBREE franchise in endometriosis and uterine fibroids.
• TherapeuticsMD: Specialty women's health biopharmaceutical company focused on hormone-related therapeutics, including uterine fibroid and menopause indications. Closely aligned with Myovant's MYFEMBREE women's health portfolio.
• Ferring Pharmaceuticals: Specialty biopharmaceutical company with established reproductive health and urology franchises. Directly comparable specialty peer to Myovant in women's health and prostate cancer therapeutics.
• Tolmar Pharmaceuticals: Specialty pharmaceutical company focused on urology and oncology, including prostate cancer treatments. Directly comparable specialty competitor to Myovant in the urologic oncology space.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/myovant
• LinkedInlinkedin.com/company/myovant-sciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds5 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Myovant Sciences